Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients

Molecular Diagnosis and Therapy

Volumn 14, Issue 3, 2010, Pages 163-169

  Bujko, Mateusz ^a   Kober, Paulina ^a   Matyja, Ewa ^b   Nauman, Paweł ^a   Dyttus Cebulok, Katarzyna ^a   Czeremszyska, Beata ^c   Bonicki, Wiesław ^a   Siedlecki, Janusz A ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c Hospital of the Ministry of Internal Affairs and Administration   (Poland)

Author keywords

biomarkers; diagnostics; genotyping; glioblastoma

Indexed keywords

DNA; FORMALDEHYDE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; PARAFFIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CODON; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE IDENTIFICATION; GENETIC SCREENING; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE;

ADULT; AGED; BIOLOGICAL ASSAY; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; YOUNG ADULT;

EID: 77954133574     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256369     Document Type: Article

References (26)

1. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008 Jan; 9 (1): 29-38
2. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007 May; 170 (5): 1445-1453
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 Mar 10; 352 (10): 987-996
4. Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 1999 Oct 22; 274 (43): 30527-30533
5. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009 Jan; 30 (1): 7-11
6. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009 Jul 15; 125 (2): 353-355
7. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009 Oct; 118 (4): 469-474
8. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009 Sep 10; 361 (11): 1058-1066
9. Jennings GT, Minard KI, McAlister-Henn L. Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase. Biochemistry 1997 Nov 4; 36 (44): 13743-13747
10. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 Dec 10; 462 (7274): 739-744
11. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (NY) 2009 Apr 10; 324 (5924): 261-265
12. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (NY) 2008 Sep 26; 321 (5897): 1807-1812
13. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progressionfree and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009 Dec 1; 27 (34): 5743-5750
14. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009 Feb 19; 360 (8): 765-773
15. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009 Apr; 174 (4): 1149-1153
16. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009 Sep 1; 27 (25): 4150-4154
17. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009 Oct 1; 15 (19): 6002-6007
18. Horbinski C, Kofler J, Kelly LM, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009 Dec; 68 (12): 1319-1325
19. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602
20. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of theDNArepair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999 Feb 15; 59 (4): 793-797
21. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003 Dec; 17 (12): 2257-2317
22. Parsons BL, Heflich RH. Genotypic selectionmethods for the direct analysis of point mutations. Mutat Res 1997 Oct; 387 (2): 97-121
23. Meyer J, Pusch S, Balss J, et al. PCR- and restriction endonucleasebased detection of IDH1 mutations. Brain Pathol 2010 Mar; 20 (2): 298-300
24. Kato Y, Jin G, Kuan CT, et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009 Dec 18; 390 (3): 547-551
25. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009 Nov; 118 (5): 599-601
26. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutationspecific IDH1 antibody binding in brain tumors. Brain Pathol 2010 Jan; 20 (1): 245-254